# Linus Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/linus-biotechnology

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.linusbio.com
- Total disclosed funding: $26M
- Latest round: Series A (May 11, 2023)
- Investors on record: 5

## About

Based in New York, US, and founded in 2020, Linus Biotechnology Inc operates as a biotechnology company that uses Retrospective Exposome Sequencing and focuses on research and development of mapping the physiological molecular dynamics. The company was Co-founded by Manish Arora (CEO), Christine Austin, and Paul Curtin. In January 2023, Linus Biotechnology Inc. raised USD 16 million in series A funding co-led by Bow Capital and GreatPoint Ventures.

The firm offers research and development for treating and diagnosing diseases using Retrospective Exposome Sequencing. The platform offered by the firm is used for diagnostics, objective endpoints in clinical trials, measurement of the therapeutic effect of investigational compounds, and outcome measurement.

## Funding rounds

- Series A, May 11, 2023, $8M — Bow Capital, David Bellet Family Office, Y.A.C. HOLDINGS CO.,LTD.
- Series A, Mar 11, 2022, $18M — GreatPoint Ventures, Bow Capital, Divergent Investments, David Bellet Family Office

## Investors

- GreatPoint Ventures (https://capitalatlas.ai/funds/greatpoint-ventures) — Series A
- Bow Capital (https://capitalatlas.ai/funds/bow-capital) — Series A
- Divergent Investments (https://capitalatlas.ai/funds/divergent-investments) — Series A
- David Bellet Family Office — Series A
- Y.A.C. HOLDINGS CO.,LTD. — Series A